Vaxart Inc
Change company Symbol lookup
Select an option...
VXRT Vaxart Inc
CIHHF China Merchants Bank Co Ltd
BBY Best Buy Co Inc
BDGE Bridge Bancorp Inc
FFIC Flushing Financial Corp
TSC TriState Capital Holdings Inc
CSQPF Cervus Equipment Corp
IMXI International Money Express Inc
MDCO Medicines Co
TVETF Traverse Energy Ltd
Go

Health Care : Biotechnology | Small Cap ValueCompany profile

Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.

Closing Price
$2.13
Day's Change
0.045 (2.16%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.35
Day's Low
2.00
Volume
(Light)
Volume:
493,028

10-day average volume:
3,555,464
493,028

Canopy Rivers Engages Hybrid Financial for Investor Relations Services

12:23 pm ET January 3, 2019 (Globe Newswire) Print

Canopy Rivers Inc. (the "Company" or "Canopy Rivers") (TSXV: RIV) today announced that it has retained Hybrid Financial Ltd. ("Hybrid"), a marketing and retail distribution services company, to provide certain investor relations services.

"We are confident that Hybrid will help us increase market awareness and further engage with the investment community," said Daniel Pearlstein, EVP, Strategy at Canopy Rivers.

Hybrid has been retained for an initial term of six months. Hybrid will be paid a monthly fee of C$14,000 and has been granted options to purchase up to 120,000 shares of the Company at a price of $3.50 per share. The options shall vest in quarterly increments beginning three months following the grant and all options shall expire within 12 months of the grant except for the final tranche which will expire three months following those options vesting. The agreement with Hybrid and the options granted thereby are subject to the approval of the TSX Venture Exchange.

About Canopy Rivers Inc.

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers works collaboratively with Canopy Growth Corporation (TSX: WEED, NYSE: CGC) to identify strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem.

Forward-Looking Statements

This news release contains statements which constitute "forward-looking information" within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" or similar expressions including: ability to increase market awareness and engage with the investment community; and expectations for other economic, business, and/or competitive factors.

Investors are cautioned that forward-looking information is not based on historical facts but instead reflects management's expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: regulatory and licensing risks; changes in general economic, business and political conditions, including changes in the financial markets; potential conflicts of interest; the Canadian regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; changes in applicable laws; compliance with extensive government regulation; public opinion and perception of the cannabis industry; and the risk factors set out in the joint management information circular of Canopy Rivers Corporation and the Company dated August 8, 2018, filed with Canadian securities regulators and available on the Company's profile on SEDAR at www.sedar.com.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information:

Canopy Rivers Inc.

www.canopyrivers.com

Karoline Hunter

Sr. Director, Investor Relations & Communications

E-mail: ir@canopyrivers.com

Daniel Pearlstein

Executive Vice President, Strategy

E-mail: daniel@canopyrivers.com

https://resource.globenewswire.com/media/1eb54685-9bd0-4e3f-8394-5ae460c487a2/small/cr-logo-white-background-lower-res-for-web-jpg.jpg

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.